$-0.10 EPS Expected for Rockwell Medical (RMTI); Cascade Microtech, Inc. (CSCD) Covered By 0 Bullish Analysts Last Week

October 13, 2017 - By Henry Gaston

Analysts expect Rockwell Medical Inc (NASDAQ:RMTI) to report $-0.10 EPS on November, 6.They anticipate $0.01 EPS change or 11.11% from last quarter’s $-0.09 EPS. After having $-0.14 EPS previously, Rockwell Medical Inc’s analysts see -28.57% EPS growth. About 108,546 shares traded. Rockwell Medical Inc (NASDAQ:RMTI) has declined 22.89% since October 13, 2016 and is downtrending. It has underperformed by 39.59% the S&P500.

Among 5 analysts covering Cascade Microtech (NASDAQ:CSCD), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Cascade Microtech had 6 analyst reports since September 7, 2015 according to SRatingsIntel. CLSA downgraded the shares of CSCD in report on Friday, February 5 to “Hold” rating. Craig Hallum downgraded the stock to “Hold” rating in Friday, February 5 report. The firm has “Neutral” rating by B. Riley & Co given on Friday, February 5. The rating was maintained by B. Riley & Co on Friday, January 15 with “Neutral”. The stock of Cascade Microtech, Inc. (NASDAQ:CSCD) has “Sector Perform” rating given on Monday, September 7 by RBC Capital Markets. The firm has “Hold” rating by Lakestreet given on Friday, February 5. See Cascade Microtech, Inc. (NASDAQ:CSCD) latest ratings:

It is down 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Cascade Microtech, Inc. is a designer, developer, maker and marketer of wafer probing, thermal and reliability solutions for the electrical measurement and testing of semiconductor devices. The company has market cap of $347.19 million. The Firm operates in two business divisions: Systems and Probes. It has a 30.17 P/E ratio. The Systems business segment is engaged in the sale of probe stations, thermal subsystems and reliability test systems.

Rockwell Medical, Inc. is a biopharmaceutical firm targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with services and products for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The company has market cap of $370.98 million. The Firm operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It currently has negative earnings. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection.

Among 2 analysts covering Rockwell Medical (NASDAQ:RMTI), 0 have Buy rating, 2 Sell and 0 Hold. Therefore 0 are positive. Rockwell Medical had 6 analyst reports since August 6, 2015 according to SRatingsIntel. Oppenheimer maintained the stock with “Outperform” rating in Saturday, August 22 report. Morgan Stanley initiated the stock with “Underweight” rating in Thursday, August 13 report. The stock has “Underperform” rating by Bank of America on Tuesday, November 8. On Thursday, August 13 the stock rating was upgraded by TheStreet to “Sell”. Oppenheimer maintained the shares of RMTI in report on Thursday, August 6 with “Outperform” rating.

Investors sentiment increased to 1.11 in Q2 2017. Its up 0.23, from 0.88 in 2017Q1. It increased, as 6 investors sold Rockwell Medical Inc shares while 21 reduced holdings. 11 funds opened positions while 19 raised stakes. 10.73 million shares or 3.46% more from 10.37 million shares in 2017Q1 were reported. D E Shaw & Com accumulated 224,136 shares. National Asset Management holds 0.04% or 25,550 shares. Legal And General Gru Plc stated it has 0% of its portfolio in Rockwell Medical Inc (NASDAQ:RMTI). Gru One Trading Lp accumulated 47,962 shares or 0% of the stock. Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Rockwell Medical Inc (NASDAQ:RMTI). Barrett Asset Ltd Com reported 10,500 shares. Susquehanna Group Inc Llp owns 339,473 shares or 0% of their US portfolio. Alliancebernstein Limited Partnership invested in 71,000 shares. Geode Mgmt, Massachusetts-based fund reported 400,531 shares. Raymond James holds 68,926 shares. Oakworth Capital Incorporated invested in 0.01% or 2,500 shares. Pnc Fin Services Group Incorporated accumulated 15,245 shares. Private Advisor Gru Inc Llc holds 23,200 shares or 0% of its portfolio. 27,108 were reported by Provident Invest Management Incorporated. Tiaa Cref Investment Ltd Liability Com holds 132,131 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com